http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104788567-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2015-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104788567-B |
| titleOfInvention | A kind of bispecific antibody preparation method and application of targeted mouse T lymphocyte CD3 and human tumor antigen EpCAM |
| abstract | The present invention provides a kind of bispecific antibodies, preparation method and the usage.At the same time, the mouse tumor cell line of expression source of people EpCAM albumen and the purposes of above-mentioned cell line are additionally provided.The bispecific antibody of the application can erect bridge between target cell and functional molecular (cell), excite the immune response with guiding performance, have broad application prospects in the immunization therapy of tumour.Effect experiment is carried out in an animal model for having intact immune system in tumour cell body of the invention, tumour is killed using immune system cell, and can effectively reflect the drug effect of Mediated by Bi-specific Antibodies immunocyte killing tumor cell, a fine pharmacodynamic assessment method is provided for the exploitation of the bispecific antibody drug of targeting immunocyte and tumour cell. |
| priorityDate | 2015-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 585.